Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005
about
The clinical expression of allergy in the lungs.Asthma and leukotrienes: antileukotrienes as novel anti-asthmatic drugs.Alternative strategies in the treatment of bronchial asthma.Leukotriene bronchoconstriction induced by allergen and exercise.New considerations about measuring airway hyperresponsiveness.Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.Role of leukotrienes in asthma pathophysiology.Exposure of healthy volunteers to swine house dust increases formation of leukotrienes, prostaglandin D2, and bronchial responsiveness to methacholine.The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field.Inhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2190915: a dose-response studyTargeting 5-lipoxygenase-activating protein in asthma and chronic obstructive pulmonary disease.Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005Measurement of airway hyperresponsiveness: new considerations.Inhaled leukotriene E(4), but not leukotriene D(4), increased airway inflammatory cells in subjects with atopic asthma.The 5-lipoxygenase-activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma.Effects of montelukast and budesonide on airway responses and airway inflammation in asthma.Inhibitors of 5-lipoxygenase activating protein: WO 2008/030369.Cockroach allergens induce biphasic asthma-like pulmonary inflammation in outbred mice.
P2860
Q33589463-DF99D9A2-D802-4271-A028-ADAFC1A916AAQ33595339-785F08A7-F51E-4C53-A18B-338B408AAE79Q33801225-7A27C3E2-F4F9-4AD9-8C64-B3B9F90B090BQ33836719-13D37514-B930-4CFE-B5F0-35A2A4DE85B8Q33960072-2CC870E1-A665-450D-B9B2-461F329D68CEQ33976334-A44C23D0-44EA-42AD-8A9F-FF7CF1FB0E24Q33988564-29EE5FC9-BB9D-4C41-BC5E-4B8FE5A0CD69Q35532197-AEF0D115-20B7-4C63-A12A-E904F7D0B02BQ37016080-DCF94A0C-3635-4E91-97AF-E53B3FB824F5Q37391120-70836014-4966-4422-8EAE-F727131994A0Q38248535-A3BF0278-0315-43A2-B9D8-ABE3F9083C57Q41861535-55FF4C4C-C611-423D-8251-21621BE5A27BQ42923617-FB0DBF16-61A5-4DD8-9EB9-61410856FD4BQ43796672-A7118C48-620B-4BD3-9AC4-8A7611F93851Q43829880-73068372-E6C1-4581-9693-623438155D5AQ44196721-25A12BC5-FEC6-45EF-B031-7E4DEB9D48F6Q46004115-FF1053D1-954E-4777-A613-A926232B6450Q47840187-A5FC8FE2-1026-4116-9A30-7A7C4183051F
P2860
Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Attenuation of early and late ...... protein antagonist, BAYx 1005
@ast
Attenuation of early and late ...... protein antagonist, BAYx 1005
@en
type
label
Attenuation of early and late ...... protein antagonist, BAYx 1005
@ast
Attenuation of early and late ...... protein antagonist, BAYx 1005
@en
prefLabel
Attenuation of early and late ...... protein antagonist, BAYx 1005
@ast
Attenuation of early and late ...... protein antagonist, BAYx 1005
@en
P2093
P2860
P356
P1433
P1476
Attenuation of early and late ...... protein antagonist, BAYx 1005
@en
P2093
P2860
P304
P356
10.1136/THX.52.4.348
P407
P577
1997-04-01T00:00:00Z